Stocks · Healthcare · Biotechnology
Cue Biopharma, Inc. CUE
$25.57 +1.27% Close, Oct 2, 2026 · NASDAQ · Market cap $185.8M
Strong growthExpensive vs sectorHigh risk
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $37.7M, up 354.4% from a year earlier, accelerating from 309.6% a quarter earlier.
- Operating margin widened to -262.0% from -475.2% a year earlier.
- The diluted share count rose 99.3% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 4%
- Revenue growth, 3-year CAGRTop 4%
- Revenue growth accelerationTop 6%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 1%
- Gross marginTop 5%
- Operating marginBottom 21%
- Accruals (lower is better)Top 1%
- Interest coverBottom 7%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 5%
- Free-cash-flow yieldBottom 19%
- EBITDA / enterprise valueBottom 11%
- Sales / enterprise valueBottom 50%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 47%
- 6-month returnTop 1%
- 1-year return vs S&P 500Top 46%
- Distance from 52-week highBottom 36%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 17%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 5%
- Maximum drawdown, 3 yearsBottom 7%
- Beta vs S&P 500 (lower is better)Bottom 2%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 309.6% | 354.4% | ↑ |
| Gross margin | 100.0% | 99.7% | ↓ |
| Operating margin | -475.2% | -262.0% | ↑ |
| FCF margin | -341.7% | -133.2% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 354.4% | 309.6% | ↑ | Top 4% |
| Gross margin | 99.7% | 100.0% | ↓ | Top 5% |
| Operating margin | -262.0% | -475.2% | ↑ | Bottom 21% |
| Net margin | -435.8% | -469.3% | ↑ | — |
| Free-cash-flow margin | -133.2% | -341.7% | ↑ | — |
| Return on invested capital | -887.3% | — | Bottom 1% | |
| Revenue growth, 3-year CAGR | 180.5% | — | Top 4% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -371.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 69.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +913.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -730.7×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -22.78%
- Shareholder yield
- -22.78%
- Share count change, 1 year
- +99.3%
- Share count change, 3-year CAGR
- +61.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 14, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -0.8%
- Positive 20 days after report
- 1 of 8
Analysts
- Consensus price target
- $83.00
- Target vs current price
- +224.6%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 14, 2026 | -1328.4% | +10.0% | -20.8% | -7.5% | — |
| May 14, 2026 | +67.3% | -14.0% | -30.7% | -8.1% | -11.4% |
| Mar 16, 2026 | +111.1% | +9.9% | -6.3% | +66.5% | +257.7% |
| Nov 12, 2025 | +25.0% | -2.2% | -15.1% | -30.1% | -52.7% |
| Aug 12, 2025 | +30.8% | -5.0% | -1.5% | -7.3% | -13.2% |
| May 12, 2025 | -21.7% | -3.7% | -7.0% | -18.3% | +0.4% |
| Mar 31, 2025 | -51.2% | -1.0% | -26.6% | -14.1% | -14.6% |
| Nov 14, 2024 | +6.7% | +0.0% | -27.3% | -30.0% | -11.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -$24.14 | -$1.69 | -1328.4% | $7.9M |
| May 14, 2026 | -$1.08 | -$3.30 | +67.3% | $5.7M |
| Mar 16, 2026 | $0.30 | -$2.70 | +111.1% | $21.9M |
| Nov 12, 2025 | -$2.10 | -$2.80 | +25.0% | $2.1M |
| Aug 12, 2025 | -$2.70 | -$3.90 | +30.8% | $3.0M |
| May 12, 2025 | -$5.11 | -$4.20 | -21.7% | $421,000 |
| Mar 31, 2025 | -$3.90 | -$2.58 | -51.2% | $1.6M |
| Nov 14, 2024 | -$5.11 | -$5.48 | +6.7% | $3.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 4.71× | — | — | Bottom 50% |
| Free-cash-flow yield | -27.01% | — | — | Bottom 19% |
| Earnings yield | -105.61% | — | — | Bottom 5% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 107
- 50-day average slope (20 days)
- -1.7%
- 200-day average slope (20 days)
- +7.1%
- Distance from 50-day average
- -11.0%
- Distance from 200-day average
- +27.2%
- RSI (14)
- 42.6
- Relative volume
- 0.35×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 125.9%
- Volatility vs own 5-year history
- 82th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.99
- Correlation with S&P 500
- 0.26
- Current drawdown from 1-year high
- -32.4%
- Maximum drawdown, 3 years
- -94.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 15, 2021 | Apr 6, 2026 | -99.0% | 1099 days | Not yet recovered |
| Oct 7, 2020 | Jul 27, 2021 | -38.7% | 201 days | 77 days (Nov 12, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $185.8M
- EPS, diluted (TTM)
- -$27.00
- Revenue (TTM)
- $37.7M
- 52-week range
- $4.97 – $45.50
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Gross profit | $16.7M | $1.2M | -$32.6M | $9.3M | $27.5M |
| Operating income | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.5M |
| Net income | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| EPS (diluted) | -$42.30 | -$44.70 | -$33.30 | -$21.60 | -$8.40 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $1.6M | $421,000 | $3.0M | $2.1M | $21.9M | $5.7M | $7.9M |
| Net income | -$8.7M | -$9.5M | -$12.3M | -$8.5M | -$7.4M | $1.6M | -$5.2M | -$153.1M |
| EPS (diluted) | -$5.10 | -$3.90 | -$5.10 | -$2.66 | -$2.21 | $0.43 | -$1.08 | -$24.14 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$38.8M | -$41.8M | -$40.0M | -$36.3M | -$21.7M |
| Capital expenditure | -$913,039 | -$171,000 | $0 | -$66,000 | -$177,000 |
| Free cash flow | -$39.8M | -$42.0M | -$40.0M | -$36.4M | -$21.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $17.4M | $39.3M | $13.4M | $14.2M | $30.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $17.4M
- Total assets
- $30.7M
- Total liabilities
- $28.4M
- Total debt
- $8.8M
- Net debt
- -$8.6M
- Shareholders’ equity
- $2.3M
As of Jun 30, 2026 (filed Aug 14, 2026).
Short interest
- Shares sold short
- 332,105
- Days to cover
- 2.44
- Change vs previous report
- +4.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Apr 24, 2026
- 1-for-30